At GU-ASCO 2014, there was a significant body of research
presented involving several novel therapies targeting the androgen pathway for the treatment of castration-resistant prostate cancer (CRPC). This included several important studies involving two approved agents, the androgen-synthesis inhibitor abiraterone and the androgen-receptor antagonist enzalutamide.
Cite as: Can Urol Assoc J 2014;8(3-4Suppl2):S8-12. http://dx.doi.org/10.5489/cuaj.2013
Published online April 14, 2014.